“an increasing trend”

For PD patients, an increasing trend of the daily peritoneal ultrafiltration (UF) was observed after SV treatment [median, IQR: 400 (200–500) vs. 500 (200–850), p = 0.114] compared to the control group [median, IQR: 450 (128–762) vs. 475 (300–800), p = 0.477].

Compared with group RF, the incidence of hypotension showed an increasing trend in the restrictive group (5 versus 1, P = 0.118), though this trend was not clinically significant (Table 4 ).

337.84±21.49 μL, p < 0.01); however, the pBOO+USCs group exhibited an increasing trend and finally demonstrated similar voided volume as the control group in the 19 th week (340.75±16.93 vs. 316.51±16.23 μL, respectively, p = 0.119) (Fig. 1E ).

Compared with the normal group, the diaphragm dysfunction group presented an increasing trend ( p = 0.119, p = 0.073) in the postoperative ICU or hospital stay.

The proportion of morning stiffness ( p = 0.015), joint deformity ( p = 0.015), and interstitial lung disease (ILD) ( p = 0.001) in ACPA + RA patients was significantly higher than in ACPA - RA patients, and disease activity score using 28 joint counts (DAS28)-ESR (3) also showed an increasing trend ( p = 0.120).

Since respiration declined more than growth, CUE exhibited an increasing trend ( F = 2.6, p = 0.12), rising from 0.22 in the control to 0.27 in the OTC treatment (Figure 6C ).

Self-esteem showed an increasing trend from 30.14 (SD 4.21) to 31.92 (SD 4.38) ( p = 0.120).

Incidence among males aged 15–19 years shifted in 2010 from an increasing trend (APC from 2006 to 2010 = 27.0; P = 0.12) to a decreasing trend (APC from 2010 to 2014 = −14.3; P = 0.25), although neither segment was significant ( Table 2 , Fig. 1 ).

7.1 months, p = 0.002) and showed an increasing trend in OS (16.9 vs. 11.3 months, p = 0.12).

Pomegranate extract (PE) supplementation led to the augmentation of circulating propionate levels ( p = 0.02) and an increasing trend for acetate levels ( p = 0.12).

However, there was a significant decrease in CD31 expression and an increase of the non‐endothelial marker CD45 combined with an increasing trend in CD14 ( P = .1201) when groups 1 and 3 are compared.

Despite the lack of a significant difference, SMR showed an increasing trend as the dark phase increased (high density: F 2,33 = 2.249, p = 0.121; low density: F 2,33 = 3.031, p = 0.062, Figure 4 ).

Total protein content in BALF showed an increasing trend toward the PGD group [2.0 (1.8–10.0) mg/mL in the PGD group, 2.2 (1.2–5.9) mg/mL in the non-PGD group, p = 0.1213, Figure 6A ].

After treatment, compared to the VPA group, the number of times of standing upright of the BDNFp group was significantly increased, and the FUS + BDNFp-CMBs group showed an increasing trend ( p = 0.1227).

PK remained the primary surgical approach for repeat corneal transplants, while the proportion of EK showed an increasing trend (r = 0.520, P = 0.123; Fig. 1 ), and DALK showed a decreasing trend (r = −0.415, P = 0.233).

The pooled analysis revealed a statistically significant improvement in Bio-C bond strength with sonic activation ( p = 0.026), while AH Plus showed an increasing trend that did not reach significance ( p = 0.124).

Although not statistically significant, ECV values showed an increasing trend across T stages: 25.8 ± 5.9 % in T1, 42.1 ± 3.0 % in T2, and 40.6 ± 4.1 % in T3 tumors (p = 0.125).

6C ), whereas TF expression (1.19±0.22-fold variation to control) showed an increasing trend in the unilateral varicocele group (p=0.1257) ( Fig. 6B ) .

Results After 3 months of intervention, blood samples of 17 participants were collected and following results were reported (1) percentage of CD34+ cells increased significantly after 3 months of CYP practice (from 18.18±7.32 cells/μL to 42.48±18.83 cells/μL) (effect size: W, 0.40; 95% CI, p = 0.001) (2) neurogenesis marker, ie, BDNF showed a significant change with time after 3 months of CYP intervention (effect size: W, 0.431, 95% CI; p = 0.002), (3) HDL showed an increasing trend (non-significant) after three months of CYP practice (53.017±1.28 mg/dl to 63.94±5.66 mg/dl) (effect size: W, 0.122; 95% CI; p = 0.126) (4) General Health score (10.64 ± 3.53 to 6.52 ± 3.12) (effect size: d, 0.98; 95% CI; p = 0.001) along with visual and executive function improved (69.94±26.21 to

2 C), while the myofibroblast marker, ACTA2 , which encodes alpha smooth muscle actin (αSMA), showed an increasing trend that did not achieve statistical significance (1.24 ± 0.13-fold; P = 0.1263) (Fig. 2 D).

Similarly, we failed to observe statistical significance in any of these categories, despite the overall HT showing an increasing trend in hs‐cTnT elevated patients (13.8% vs 7.4%, P = .128, OR 2.016, 95% CI 0.817‐4.969, Table 2 ). 3.3.

In M1 macrophages, lactate levels follow an increasing trend ( p = 0.128), which is also in line with the HP results.

Moreover, in the current study, the proportion of patients treated with induction chemotherapy in LARC showed an increasing trend (44% vs. 60%, p = 0.129), in part due to MEND-IT trial investigating the benefit of FOLFOXIRI induction chemotherapy in LARC [ 24 ].

In Poland, we observed an increasing trend in the total number of amputations due to DFU compared with the pre-COVID era (5292 in 2017–2019 (combined and averaged data) vs. 5869 in 2020, p = 0.13).

Cspg4 mRNA levels showed an increasing trend after 4 days of rhC3 treatment ( P = 0.13), and Mog mRNA levels were significantly reduced in rhC3-treated group ( P = 0.044).